• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Ligand Pharmaceuticals Incorporated

    5/13/26 4:09:16 PM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LGND alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001223000
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    LIGAND PHARMACEUTICALS INCORPORATED
    SEC File Number
    001-33093
    Address of Issuer
    555 Heritage Drive, Suite 200
    Jupiter
    FLORIDA
    33458
    Phone
    (858) 550-7500
    Name of Person for Whose Account the Securities are To Be Sold
    JOHN KOZARICH
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    1575352012.502004106105/13/2026
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common05/13/2026Stock Option ExerciseIssuerCheckbox not checked157505/13/2026Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    JOHN KOZARICH
    555 Heritage Drive, Suite 200
    Jupiter � FL � 33458
    Common05/12/2026459102816.00
    JOHN KOZARICH
    555 Heritage Drive, Suite 200
    Jupiter � FL � 33458
    Common05/01/2026467111519.60
    JOHN KOZARICH
    555 Heritage Drive, Suite 200
    Jupiter � FL � 33458
    Common04/01/202646794440.09
    JOHN KOZARICH
    555 Heritage Drive, Suite 200
    Jupiter � FL � 33458
    Common03/02/202646793632.37

    144: Remarks and Signature

    Remarks
    Date of Notice
    05/13/2026

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ John W Kozarich

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $LGND alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LGND

    DatePrice TargetRatingAnalyst
    3/11/2026$244.00Buy
    BofA Securities
    12/9/2025$270.00Buy
    Citigroup
    4/10/2025$143.00Buy
    Stifel
    10/3/2024$135.00Outperform
    Oppenheimer
    7/30/2024$130.00Outperform
    RBC Capital Mkts
    2/22/2022$180.00 → $130.00Buy
    Benchmark
    2/18/2022$185.00 → $165.00Overweight
    Barclays
    9/22/2021$174.00 → $180.00Overweight
    Barclays
    More analyst ratings

    $LGND
    SEC Filings

    View All

    SEC Form DEFA14A filed by Ligand Pharmaceuticals Incorporated

    DEFA14A - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)

    5/18/26 9:03:04 AM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Ligand Pharmaceuticals Incorporated

    8-K - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)

    5/18/26 9:01:36 AM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Ligand Pharmaceuticals Incorporated

    144 - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)

    5/13/26 4:09:16 PM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGND
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ligand to Participate in June Investor Conferences

    JUPITER, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its senior management team will participate in the following upcoming investor conferences: Stifel 2026 Boston Cross Sector 1x1 Conference. Management will participate in one-on-one meetings with investors on June 3, 2026 in Boston.Goldman Sachs 47th Annual Global Healthcare Conference. Management will participate in a fireside chat on June 10, 2026 at 10:00 a.m. ET in Miami followed by one-on-one meetings with investors. Investors interested in arranging one-on-one meetings should contact their Stifel or Goldman Sachs representative. About Ligand PharmaceuticalsLigand

    5/27/26 4:01:00 PM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

    Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial ("BACKBEAT Trial") by the end of Q3 2026Medtronic (NYSE:MDT) and Orchestra BioMed intend to pursue late-breaking clinical trial presentation at major cardiology conference in Q2 2027 and subsequent marketing application submission to FDA and global regulatory agencies, assuming primary endpoints are met FDA granted a second Breakthrough Device Designation ("BDD") for AVIM Therapy specific to patients with uncontrolled hypertension despite the use of anti-hypertensive medications, and an indication for a pacemakerVirtue Trial sites progressing with site activation and patient enrollment acceleration continuing t

    5/12/26 4:18:12 PM ET
    $LGND
    $MDT
    $OBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medicinal Chemicals and Botanical Products

    Ligand Reports First Quarter 2026 Financial Results

    First quarter performance driven by strong year-over-year royalty revenue growth of 56% Reaffirms Previously Raised 2026 Full-Year Financial Guidance Reflecting Anticipated Partial-Year Contribution from Pending XOMA Royalty Acquisition Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2026, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss the results and answer questions. "The first few months of 2026 have al

    5/7/26 7:00:00 AM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGND
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Davis Todd C bought $1,000,456 worth of shares (9,510 units at $105.20), increasing direct ownership by 6% to 161,234 units (SEC Form 4)

    4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

    5/13/25 8:05:16 PM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Espinoza Octavio bought $156,090 worth of shares (1,500 units at $104.06), increasing direct ownership by 6% to 27,932 units (SEC Form 4)

    4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

    5/13/25 8:04:05 PM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Davis Todd C bought $243,480 worth of shares (2,500 units at $97.39), increasing direct ownership by 2% to 123,010 units (SEC Form 4)

    4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

    8/9/24 5:52:17 PM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGND
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CLO & Secretary Reardon Andrew sold $1,135,316 worth of shares (5,000 units at $227.06) as part of a pre-agreed trading plan and exercised 5,000 shares at a strike of $52.27 (SEC Form 4)

    4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

    6/2/26 6:22:18 PM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Espinoza Octavio exercised 1,736 shares at a strike of $57.58, increasing direct ownership by 7% to 27,679 units (SEC Form 4)

    4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

    5/28/26 7:43:04 PM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kozarich John W sold $563,080 worth of shares (2,501 units at $225.14) as part of a pre-agreed trading plan and exercised 2,034 shares at a strike of $69.51, decreasing direct ownership by 1% to 41,786 units (SEC Form 4)

    4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

    5/14/26 9:08:34 PM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGND
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities initiated coverage on Ligand Pharma with a new price target

    BofA Securities initiated coverage of Ligand Pharma with a rating of Buy and set a new price target of $244.00

    3/11/26 8:38:58 AM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Ligand Pharma with a new price target

    Citigroup initiated coverage of Ligand Pharma with a rating of Buy and set a new price target of $270.00

    12/9/25 8:50:31 AM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Ligand Pharma with a new price target

    Stifel initiated coverage of Ligand Pharma with a rating of Buy and set a new price target of $143.00

    4/10/25 12:42:08 PM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGND
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ligand Pharmaceuticals Incorporated

    SC 13G/A - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)

    11/1/24 4:07:52 PM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Ligand Pharmaceuticals Incorporated

    SC 13G - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)

    2/14/24 6:26:25 AM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Ligand Pharmaceuticals Incorporated (Amendment)

    SC 13G/A - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)

    2/13/24 5:08:05 PM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGND
    Financials

    Live finance-specific insights

    View All

    Ligand Reports First Quarter 2026 Financial Results

    First quarter performance driven by strong year-over-year royalty revenue growth of 56% Reaffirms Previously Raised 2026 Full-Year Financial Guidance Reflecting Anticipated Partial-Year Contribution from Pending XOMA Royalty Acquisition Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2026, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss the results and answer questions. "The first few months of 2026 have al

    5/7/26 7:00:00 AM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator

    Transaction expands Ligand's royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand's long-term compounding growth, adding a complementary portfolio across development stages, therapeutic areas, and modalities to broaden patient access and improve lives Acquisition is expected to be immediately accretive to Ligand adjusted EPS; Ligand increases 2026 adjusted EPS guidance to $8.50-$9.501 and expects the transaction to be accretive by $1.50 per share to adjusted EPS in 20272 Ligand to hold investor call at 8:00 a.m. ET today JUPITER, Fla. and EMERYVILLE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporate

    4/27/26 7:00:00 AM ET
    $LGND
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ligand to Report First Quarter 2026 Financial Results on May 7, 2026

    JUPITER, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026. The company will hold a conference call beginning at 8:30 a.m. Eastern time to discuss the results and provide a general business update. Conference Call and Webcast Information   Date:  Thursday, May 7, 2026   Time: 8:30 a.m. Eastern time   Conference Call: United States (Local): +1 (585) 542-9983 United States (Toll-Free): +1 (833) 461-5787 International: Global Dial-in NumbersMeeting ID: 304603090   Webcast: Live and replay webcasts of the call are available here.    About LigandLigand is a

    4/22/26 7:00:00 AM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGND
    Leadership Updates

    Live Leadership Updates

    View All

    Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement

    The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity private placement Combined company will operate under the name "Pelthos Therapeutics Inc." and will trade on the NYSE American exchange under the ticker symbol "PTHS" starting on July 2, 2025 DURHAM, N.C., July 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc., a biopharmaceutical company committed to commercializing innovative therapeutic products for high unmet patient needs, today announced the closing of the previously announced merger agreement pursuant to which CHRO Me

    7/2/25 7:00:00 AM ET
    $CHRO
    $LGND
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer

    WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced the appointment of Matthew E. Korenberg as Chief Financial Officer, effective immediately. Mr. Korenberg is a seasoned operational and financial leader with more than 27 years of senior executive experience in biotech companies and healthcare investment banking. Throughout his career, he has focused on capital raising, partnering and licensing deals, acquisitions, as well as overseeing p

    10/17/24 7:30:00 AM ET
    $LFCR
    $LGND
    $PIRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OmniAb Announces Completion of Spin-Off and Business Combination

    Leading Antibody Discovery Technologies Enable Development of Innovative Therapeutics Regular-way Trading of OABI Begins November 2, 2022 on Nasdaq OmniAb, Inc. (NASDAQ:OABI) today announced the completion of the expected tax-free spin-off from Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and the subsequent business combination with Avista Public Acquisition Corp. II (NASDAQ:AHPA), resulting in OmniAb becoming an independent publicly traded company. Based on actual redemptions and estimated transaction expenses, OmniAb expects to have approximately $95 million in cash at closing. OmniAb will begin regular-way trading November 2, 2022 on Nasdaq under the stock ticker symbol "OABI." "

    11/1/22 4:01:00 PM ET
    $AHPA
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care